IOVA in the 13F filings
Iovance Biotherapeutics Inc · CUSIP 462260100
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 24
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 1 listed it in both
- Shares listed
- 53,315,504
- combined, among listed positions
- Reported value
- $187m
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 20 buyers (opened or added shares) and 6 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +20,650,729.
Managers listing IOVA in Q1 2026
24 of 24 holders
Largest increases and reductions, by shares
Increases
- Two Sigma Investments LPexisting position · 13,687,433 shares now+9,289,444
- D. E. Shaw & Co.existing position · 8,016,353 shares now+4,186,558
- Millennium Management LLCexisting position · 9,414,292 shares now+2,828,760
- Marshall Wace LLPnew position · 2,355,612 shares now+2,355,612
- T. Rowe Price Associates Incexisting position · 3,166,861 shares now+1,975,033
Reductions
- Susquehanna International Group LLPexisting position · 2,996,743 shares now-1,951,871
- Walleye Capital LLCexisting position · 30,356 shares now-792,398
- Citadel Advisors LLCexisting position · 2,611,345 shares now-531,746
New positions and exits
New (4)
Exited (3)
- Renaissance Technologies LLCwas $1.8m
- Brevan Howard Capital Management LPwas $1.4m
- ExodusPoint Capital Management LPwas $768k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2017 | 1 | $6.6m | n.a. | n.a. |
| Q4 2017 | 1 | $15m | n.a. | n.a. |
| Q1 2018 | 4 | $72m | n.a. | n.a. |
| Q2 2018 | 3 | $59m | n.a. | n.a. |
| Q3 2018 | 3 | $59m | n.a. | n.a. |
| Q4 2018 | 6 | $73m | n.a. | n.a. |
| Q1 2019 | 5 | $70m | n.a. | n.a. |
| Q2 2019 | 5 | $198m | n.a. | n.a. |
| Q3 2019 | 6 | $166m | n.a. | n.a. |
| Q4 2019 | 7 | $333m | n.a. | n.a. |
| Q1 2020 | 9 | $610m | n.a. | n.a. |
| Q2 2020 | 8 | $624m | n.a. | n.a. |
| Q3 2020 | 9 | $822m | n.a. | n.a. |
| Q4 2020 | 9 | $1.8bn | n.a. | n.a. |
| Q1 2021 | 8 | $1.2bn | n.a. | n.a. |
| Q2 2021 | 6 | $917m | n.a. | n.a. |
| Q3 2021 | 7 | $753m | n.a. | n.a. |
| Q4 2021 | 8 | $517m | n.a. | n.a. |
| Q1 2022 | 8 | $423m | n.a. | n.a. |
| Q2 2022 | 7 | $121m | n.a. | n.a. |
| Q3 2022 | 8 | $100m | n.a. | n.a. |
| Q4 2022 | 6 | $43m | n.a. | n.a. |
| Q1 2023 | 6 | $102m | n.a. | n.a. |
| Q2 2023 | 4 | $102m | n.a. | n.a. |
| Q3 2023 | 4 | $35m | n.a. | n.a. |
| Q4 2023 | 7 | $105m | 3 | 4 |
| Q1 2024 | 5 | $154m | 2 | 3 |
| Q2 2024 | 4 | $98m | 1 | 2 |
| Q3 2024 | 4 | $93m | 1 | 2 |
| Q4 2024 | 3 | $52m | 1 | 1 |
| Q1 2025 | 3 | $19m | 1 | 1 |
| Q2 2025 | 1 | $45k | 0 | 1 |
| Q3 2025 | 1 | $56k | 0 | 0 |
| Q4 2025 | 1 | $71k | 15 | 5 |
| Q1 2026 | 2 | $1.3m | 20 | 6 |
| Q2 2026 | 1 | $79m | 15 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
IOVA and GILD →IOVA and AMGN →IOVA and ARGX →Choose a stock to compare with IOVA →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own IOVA, latest filings →Back to the 13F Explorer →